Physician profile
Mark G Friedman
NPI 1467404848
$1,341.20
in general payments reported to CMS, 2019-2025
14 companies · $249 in 2025
The $249 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $38.13 · 2020: $40.02 · 2021: $237 · 2022: $149 · 2023: $327 · 2024: $301 · 2025: $249.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $877.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $876.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $729.91 | 2022-2025 | |
| Abbott Laboratories | $174.27 | 2021 | |
| Abbvie INC. | $173.68 | 2021-2023 | |
| Boston Scientific Corporation | $54.52 | 2019-2025 | General - Pain Management |
| Upsher-Smith Laboratories LLC | $50.35 | 2022 | |
| Amgen INC. | $32.59 | 2025 | Evenity |
| Ge Healthcare | $22.00 | 2025 | |
| Biogen, INC. | $21.36 | 2024 | Leqembi |
| E.R. Squibb & Sons, L.L.C. | $19.00 | 2025 | Orencia |
| Glaxosmithkline, LLC. | $14.65 | 2020 | |
| Currax Pharmaceuticals LLC | $12.83 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $12.68 | 2019 | |
| Sanofi Pasteur INC. | $12.54 | 2020 | |
| Merck Sharp & Dohme LLC | $10.82 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Friedman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.